AI commercialization provider RoseRx expands in US on strong pharma demand

Boston, United States – RoseRx, the agentic AI commercialization platform for pharmaceutical and life science brands, has announced its expansion into the US with a new office in Boston.

The company is establishing a US presence in response to demand from existing global pharmaceutical clients for its compliant conversational AI platform.

RoseRx co-founder and CEO Romain Bonjean said:
"Recent consolidation in the pharma AI commercialisation category has validated strong demand for conversational AI platforms and paves the way for RoseRx as the independent, multi-agent successor in this fast-growing space."

The company has been serving US customers from Sydney since late 2025 and its business has grown rapidly in the first three months of 2026.

RoseRx provides pharma commercial and medical affairs teams with AI agents for patient engagement, field force enablement and doctor interactions, all grounded in medical, legal and regulatory approved brand content. A built-in review module streamlines end-to-end medical, legal and regulatory approval workflows with version control, audit trails and accelerated review process time.

The company's US expansion has been boosted by its recent selection for the PharmStars Pharmatech Innovation Summit in Boston on 12 May 2026, chosen from nearly 100 applicants.

PharmStars is funded by Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, Roche, Sanofi, and Takeda. Alumni have raised more than US$900 million and entered 100 pharmaceutical partnerships.